News | December 10, 2008

Heart Rhythm Society Says Measures Are In Place to Ensure Safety of EP Devices

December 11, 2008 - The Heart Rhythm Society is reiterating its position on the importance of device and lead reliability and safety following the publication of “Learning from Our Mistakes? Testing New ICD Technology” by Robert Hauser, M.D., and Adrian Almquist, M.D., as well as a corresponding letter from Mitchell Shein and Daniel Schultz from the FDA, which were published in the Dec. 11 issue of the New England Journal of Medicine.

“The Heart Rhythm Society is committed to the highest standard of patient safety,” said N.A. Mark Estes, president of the Heart Rhythm Society. “We have been at the forefront of establishing policies and guidelines to ensure the safety of life-saving devices such as internal cardiac defibrillators (ICDs) and pacemakers. The society will continue to develop standards as technology continues to evolve.”

To address issues regarding the safety of device leads, the Heart Rhythm Society created a task force earlier this year with leading experts and is currently collaborating with regulatory agencies, industry and patients to develop recommendations regarding lead performance. The Heart Rhythm Society anticipates releasing the new recommendations at Heart Rhythm 2009, the society’s annual scientific sessions which will take place in Boston in May.

The society’s recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs), released in September 2006, have been adopted by physicians, government and industry and helped to achieve greater transparency in the post-market surveillance, analysis and reporting of information; the establishment of new systems to identify malfunctioning devices more quickly; and standard notification and communication to physicians and patients from the manufacturer when a device malfunction is identified.

For more information: www.HRSonline.org

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init